Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations
Modern Rheumatology · 04.11.2026 · 36 (6) · 861-868
DOI: 10.1093/mr/roag080 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Modern Rheumatology, online erschienen am 01.09.2026. Verfasst von Shigeru Iwata und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Methotrexate, Antirheumatic Agents, Neoplasms. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In this review, we summarized the current evidence on the risks of incident malignancy and cancer recurrence in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX). Before considering the effect of MTX, it is important to recognize the malignancy risk associated with RA itself. The overall risk of malignancy in patients with RA modestly increased, as per two meta-analyses, although Japanese studies report inconsistent findings, with one showing a slight decrease and another a slight increase. The risk of malignant lymphoma is increased, whereas the risk of colorectal cancer appears to be reduced. Additionally, there are concerns regarding the increased risk of lung and skin cancers. However, there is limited evidence specific to patients with RA treated with MTX. According to an Australian report, these patients have a higher risk of overall malignancy, along with an increased risk of malignant lymphoma, lung cancer, and melanoma. Studies comparing MTX with tumour necrosis factor inhibitors have reported no significant difference in the overall malignancy risk or increased malignancy risk. In White patients, MTX has been associated with an increased risk of recurrence in patients with RA and a history of non-melanoma skin cancer. There is insufficient evidence regarding the risks of MTX use in patients with RA and malignancy. Therefore, decisions regarding MTX use should be made individually based on shared decision-making, and careful follow-up is necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan.
- Department of Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan.
- Health Science Research and Development Center (HeRD), Institute of Science Tokyo Hospital, Tokyo, Japan.
- Rheumatology, Hiroshima Rheumatology Clinic, Hiroshima, Japan.
- Health Sciences Department of Nursing, Kansai University of International Studies, Miki, Japan.
- Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo Japan.
ORCID-Profile: Shigeru Iwata
Zitieren
APA
Iwata, S., Tada, M., Koike, R., Yamanishi, Y., Fusama, M., Tsuchiya, H., Yamaoka, K., & Kameda, H. (2026). Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations. Modern Rheumatology, 36(6), 861-868. https://doi.org/10.1093/mr/roag080
Vancouver
Iwata S, Tada M, Koike R, Yamanishi Y, Fusama M, Tsuchiya H, et al. Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations. Modern Rheumatology. 2026;36(6):861-868. doi:10.1093/mr/roag080
BibTeX
@article{Iwata2026,
author = {Iwata, Shigeru and Tada, Masahiro and Koike, Ryuji and Yamanishi, Yuji and Fusama, Mie and Tsuchiya, Haruka and Yamaoka, Kunihiro and Kameda, Hideto},
title = {Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations},
journal = {Modern Rheumatology},
year = {2026},
volume = {36},
number = {6},
pages = {861--868},
doi = {10.1093/mr/roag080}
}
EUVIMED